Yogesh Bhattarai

Dr. Yogesh Bhattarai

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Cell Host & Microbe
Verified
Journal Article
Closed access
YBYogesh Bhattarai
Yogesh Bhattarai
BWBrianna B. Williams
Brianna B. Williams
EBEric J. Battaglioli
Eric J. Battaglioli
WWWeston R. Whitaker
Weston R. Whitaker
LTLisa Till
Lisa Till
PKPurna C. Kashyap
Purna C. Kashyap

1 September 2020 in Cell
Verified
Journal Article
Closed access
RMRuben Mars
Ruben Mars
YYYi Yang
Yi Yang
TWTonya Ward
Tonya Ward
MHMo Houtti
Mo Houtti
SPSambhawa Priya
Sambhawa Priya
PKPurna C. Kashyap
Purna C. Kashyap

1 January 2017 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Closed access
PDF file
YBYogesh Bhattarai
Yogesh Bhattarai
DPDavid A. Muniz Pedrogo
David A. Muniz Pedrogo
PKPurna C. Kashyap
Purna C. Kashyap
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal (GI) disorders. Despite its prevalence, the pathophysiology of IBS is not well understood although multiple peripheral and central factors are implicated. Recent studies suggest a role for alterations in gut microbiota in IBS. Significant advances in next-generation sequencing technology and bioinformatics and the declining cost have now allowed us to better investigate the role of gut microbiota in IBS. In the following review, we propose gut microbiota as a unifying factor in the pathophysiology of IBS. We first describe how gut microbiota can be influenced by factors predisposing individuals to IBS such as host genetics, stress, diet, antibiotics, and early life experiences. We then highlight the known effects of gut microbiota on mechanisms implicated in the pathophysiology of IBS including disrupted gut brain axis (GBA), visceral hypersensitivity (VH), altered GI motility, epithelial barrier dysfunction, and immune activation. While there are several gaps in the field that preclude us from connecting the dots to establish causation, we hope this overview will allow us to identify and fill in the voids.

1 January 2021 in Gut Microbes
Verified
Journal Article
Open access
YBYogesh Bhattarai
Yogesh Bhattarai
JSJie Si
Jie Si
MPMeng Pu
Meng Pu
OROwen A. Ross
Owen A. Ross
PMPamela J. McLean
Pamela J. McLean
PKPurna C. Kashyap
Purna C. Kashyap
Parkinson’s disease (PD) is a common neurodegenerative disorder characterized primarily by motor and non-motor gastrointestinal (GI) deficits. GI symptoms’ including compromised intestinal barrier function often accompanies altered gut microbiota composition and motor deficits in PD. Therefore, in this study, we set to investigate the role of gut microbiota and epithelial barrier dysfunction on motor symptom generation using a rotenone-induced mouse model of PD. We found that while six weeks of 10 mg/kg of chronic rotenone administration by oral gavage resulted in loss of tyrosine hydroxylase (TH) neurons in both germ-free (GF) and conventionally raised (CR) mice, the decrease in motor strength and coordination was observed only in CR mice. Chronic rotenone treatment did not disrupt intestinal permeability in GF mice but resulted in a significant change in gut microbiota composition and an increase in intestinal permeability in CR mice. These results highlight the potential role of gut microbiota in regulating barrier dysfunction and motor deficits in PD.

1 July 2017 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Closed access
PDF file
YBYogesh Bhattarai
Yogesh Bhattarai
BSBradley A. Schmidt
Bradley A. Schmidt
DLDavid R. Linden
David R. Linden
ELEric Larson
Eric Larson
MGMadhusudan Grover
Madhusudan Grover
PKPurna C. Kashyap
Purna C. Kashyap
Serotonin [5-hydroxytryptamine (5-HT)], an important neurotransmitter and a paracrine messenger in the gastrointestinal tract, regulates intestinal secretion by its action primarily on 5-HT3and 5-HT4receptors. Recent studies highlight the role of gut microbiota in 5-HT biosynthesis. In this study, we determine whether human-derived gut microbiota affects host secretory response to 5-HT and 5-HT receptor expression. We used proximal colonic mucosa-submucosa preparation from age-matched Swiss Webster germ-free (GF) and humanized (HM; ex-GF colonized with human gut microbiota) mice. 5-HT evoked a significantly greater increase in short-circuit current (Δ Isc) in GF compared with HM mice. Additionally, 5-HT3receptor mRNA and protein expression was significantly higher in GF compared with HM mice. Ondansetron, a 5-HT3receptor antagonist, inhibited 5-HT-evoked Δ Iscin GF mice but not in HM mice. Furthermore, a 5-HT3receptor-selective agonist, 2-methyl-5-hydroxytryptamine hydrochloride, evoked a significantly higher Δ Iscin GF compared with HM mice. Immunohistochemistry in 5-HT3A-green fluorescent protein mice localized 5-HT3receptor expression to enterochromaffin cells in addition to nerve fibers. The significant difference in 5-HT-evoked Δ Iscbetween GF and HM mice persisted in the presence of tetrodotoxin (TTX) but was lost after ondansetron application in the presence of TTX. Application of acetate (10 mM) significantly lowered 5-HT3receptor mRNA in GF mouse colonoids. We conclude that host secretory response to 5-HT may be modulated by gut microbiota regulation of 5-HT3receptor expression via acetate production. Epithelial 5-HT3receptor may function as a mediator of gut microbiota-driven change in intestinal secretion.NEW & NOTEWORTHY We found that gut microbiota alters serotonin (5-HT)-evoked intestinal secretion in a 5-HT3receptor-dependent mechanism and gut microbiota metabolite acetate alters 5-HT3receptor expression in colonoids.View this article's corresponding video summary at https://www.youtube.com/watch?v=aOMYJMuLTcw&feature=youtu.be .